Fig. 2
Adoptive transfer of VSSP-activated BMDMs reduce prostate tumor growth. a Schedule of treatment used in the pre-clinical trial with infused VSSP-activated BMDMs or steady state BMDMs on Ptenpc−/−; Trp53pc−/− tumor-bearing mice (n = 6–12 mice per group). 10–12 weeks old Ptenpc−/−; Trp53pc−/− tumor-bearing mice were infused weekly with 2–5 × 106 BMDMs activated or not in vitro con VSSPs. After 12 weeks the mice were euthanized and tumors were collected. b Analyses of the conditioned medium of VSSP-BMDMs compared to untreated BMDMs, tested for the indicated soluble molecules by Proteome Profiler Mouse XL Cytokine Array. Bone marrow cells were cultured in RPMI with 10% heat-inactivated FBS in presence of 30 ng/mL of M-CSF. At day 5 media was replaced by RPMI containing 10 µg/mL of VSSP. Cells were cultured for 24 h and after, media was replaced by RPMI with 10% heat-inactivated FBS, and cells were cultured for 24 h to collect the CM. The graph shows the fold change of the indicated soluble molecules. Data is a metanalysis of three independent experiments. c Prostate weight compared with untreated Ptenpc−/−; Trp53pc−/− and wild type mice. d Representative picture of prostate lobes in Ptenpc−/−; Trp53pc−/− mice upon infusion of steady state or VSSP-activated BMDMs. e Quantification of adenocarcinoma, prostatic intraepithelial neoplasia (PIN), hyperplasia or normal-like glands in Ptenpc−/−; Trp53pc−/− mice upon infusion of steady state or VSSP-activated BMDMs. f Representative H&E at the endpoint. Scale Bar 500 μm. Data is representative of at least three biological independent animals. Data in c and e is a metanalysis of two independent experiments. Symbols indicates significant differences by Tukey test c or Student t test e (*p < 0.05). BMDMs Bone marrow-derived macrophages